Download Presentations

Keynote: The European policy agenda in market access: an industry perspective

• What is on the agenda of the new European Commission and how will it change the industry?
• Find out on what level market access hurdles are and how they will affect your business in the coming years
• What industry initiatives are in place and how can they be coordinated to decrease complexity

Andrea Rappagliosi, VP European Government Affairs & Head of Brussels Office, GSK. Chair of the EuropaBio Healthcare Council.

Market Access – practical challenges for the pharmaceutical industry

• Rise above market access challenges to save time, cost and reduce risk to product roll-outs
• Bridge the gap between theory and practice and take advantage of latest developments

Janice Haigh, Senior Director, Pricing and Market Access – Europe, Astellas Pharma Europe

Keynote: The evolving regulatory landscape and its impact on decision making

• EMEA and FDA divergence and what it means for your global strategy
• Hear about new stakeholders and their influence on regulators – what does it mean for the industry?
• Key strategies to ensure optimal and current regulatory knowledge

Tracy Baskerville, VP Global Regulatory Affairs, Solvay

Title: Streamline Market Access

• Streamline your strategies in the UK and speed up product roll-out in other countries
• Get the focus right and improve your market access efforts
• Learn how you will find global approaches for regional needs

Angela McFarlane, Director, HGS Consultancy

The impact of emerging hurdles for reimbursement and Market Access on your business

• What are the additional hurdles for central reimbursement and decentral actual market access?
• Explore the impact on the sales forecast of a new drug and the associated costs
• Incorporate cost-effectiveness data in the decision-making process and make your value proposition reach its full appeal

Eline Kogels, Kogels Consultancy Network.
Dr. Mark Nuijten, Health Economist, Ars Accessus Medica, Erasmus University Rotterdam

NICE – Understand HTA policy development in the UK

• What are the effects of the new technology appraisal process to your application?
• Learn how the new evaluation pathway for medical technologies affects you
• Analyse process and content requirements including cost-effectiveness data and prescription restrictions

Dr. Elisabeth George, Associate Director – Appraisals, NICE

The role of strategy marketing: Defining market access strategies throughout a product's lifecycle 

• Find out what it takes to effectively design a market access plan that really works
• Determine a long term revenue strategy with a roadmap of stakeholders that are important throughout the brand’s lifecycle
• Understand capability requirements for market access teams – is there an advantage of being small?

Dr. Elke Hunsche, Head Health Economics & Pricing, Actelion Pharmaceuticals Ltd, Switzerland